Edition:
United Kingdom

Regenxbio Inc (RGNX.OQ)

RGNX.OQ on NASDAQ Stock Exchange Global Select Market

45.16USD
2:32pm GMT
Change (% chg)

$-0.56 (-1.22%)
Prev Close
$45.72
Open
$45.81
Day's High
$46.10
Day's Low
$45.16
Volume
5,521
Avg. Vol
182,904
52-wk High
$85.05
52-wk Low
$23.25

Latest Key Developments (Source: Significant Developments)

Rocket Pharmaceuticals And REGENXBIO Announce New License Agreement
Monday, 26 Nov 2018 

Nov 26 (Reuters) - Rocket Pharmaceuticals Inc ::ROCKET PHARMACEUTICALS AND REGENXBIO ANNOUNCE NEW LICENSE AGREEMENT FOR THE TREATMENT OF DANON DISEASE USING NAV AAV9 VECTOR.ROCKET PHARMACEUTICALS INC - INVESTIGATIONAL NEW DRUG APPLICATION EXPECTED TO BE FILED IN 2019; CLINICAL TRIAL TO FOLLOW.ROCKET PHARMACEUTICALS - REGENXBIO GRANTS CO WORLDWIDE RIGHTS TO NAV AAV9 FOR DEVELOPMENT & COMMERCIALIZATION FOR DANON DISEASE TREATMENTS.ROCKET PHARMACEUTICALS INC - UNDER TERMS OF AGREEMENT, REGENXBIO WILL RECEIVE A $7 MILLION UPFRONT PAYMENT.ROCKET PHARMACEUTICALS - REGENXBIO TO GET HIGH-SINGLE TO LOW-DOUBLE DIGIT ROYALTIES ON NET SALES OF PRODUCTS WITH LICENSED INTELLECTUAL PROPERTY.  Full Article

Regenxbio Announces Additional Positive Interim Phase I Trial Update For RGX-314
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES ADDITIONAL POSITIVE INTERIM PHASE I TRIAL UPDATE FOR RGX-314 FOR THE TREATMENT OF WET AMD AT THE AMERICAN ACADEMY OF OPHTHALMOLOGY 2018 ANNUAL MEETING.REGENXBIO INC - COMPANY CONTINUES PLANS TO PROCEED TO PHASE II CLINICAL TRIAL IN 2019.REGENXBIO INC - ADDITIONAL DATA AND PROGRAM UPDATES ARE EXPECTED IN EARLY 2019.  Full Article

REGENXBIO Announces Exclusive Worldwide License With Ultragenyx
Monday, 22 Oct 2018 

Oct 22 (Reuters) - REGENXBIO Inc ::REGENXBIO ANNOUNCES EXCLUSIVE WORLDWIDE LICENSE WITH ULTRAGENYX FOR THE TREATMENT OF CDKL5 DEFICIENCY DISORDER USING NAV VECTORS.REGENXBIO INC - WILL RECEIVE AN UPFRONT PAYMENT, ONGOING FEES, MILESTONE PAYMENTS AND ROYALTIES ON NET SALES OF PRODUCTS INCORPORATING NAV VECTORS.  Full Article

Regenxbio Announces Pipeline Expansion With Rgx-181 Gene Therapy For CLN2 Form Of Batten Disease
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES PIPELINE EXPANSION WITH RGX-181 GENE THERAPY FOR CLN2 FORM OF BATTEN DISEASE.REGENXBIO INC - INTENDS TO ADVANCE RGX-181 TO CLINICAL TRIALS WITH IND SUBMISSION EXPECTED IN 2019.  Full Article

Regenxbio Inc Files For Potential Mixed Shelf Offering
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - Regenxbio Inc ::REGENXBIO INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.REGENXBIO INC SAYS IN ADDITION, SELLING STOCKHOLDERS MAY OFFER AND SELL UP TO AGGREGATE OF 5.06 MILLION SHARES OF CO'S COMMON STOCK.  Full Article

Regenxbio Inc - Intends To Offer And Sell $175 Million Of Stock
Wednesday, 8 Aug 2018 

Regenxbio Inc ::REGENXBIO ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.REGENXBIO INC - INTENDS TO OFFER AND SELL $175 MILLION OF STOCK.  Full Article

Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Avexis Inc ::REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY.REGENXBIO INC - COULD RECEIVE UP TO $260 MILLION, INCLUDING $140 MILLION IN GUARANTEED UPFRONT AND ANNUAL PAYMENTS.REGENXBIO INC - AMENDED AGREEMENT PERMITS ASSIGNMENT BY AVEXIS UPON A CHANGE OF CONTROL WITHOUT REGENXBIO'S CONSENT.REGENXBIO INC - AVEXIS ACQUIRES EXCLUSIVE RIGHTS TO ENTIRE NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO - FOR PRODUCT DEVELOPED FOR TREATMENT OF SMA USING NAV AAV9 VECTOR, CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES ON NET SALES.  Full Article

Regenxbio Provides Year-End 2017 Corporate Update
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Regenxbio Inc ::REGENXBIO PROVIDES YEAR-END 2017 CORPORATE UPDATE.- ‍ANTICIPATE INITIATING DOSING IN CLINICAL TRIALS FOR MPS I AND MPS II IN FIRST HALF 2018​.- ‍ANTICIPATE COMPLETING DOSING AND PRESENTING TOPLINE DATA FROM RGX-314 AND RGX-501 TRIALS IN LATE 2018​.- ‍ENDED 2017 WITH GREATER THAN $175 MILLION IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES​.SAYS EXPECTS FULL-YEAR 2018 CASH BURN TO BE BETWEEN $85 MILLION AND $95 MILLION.  Full Article

Regenxbio Announces IND Active For Phase I/II Trial Of RGX-121 To Treat Mucopolysaccharidosis Type II
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Regenxbio Inc ::REGENXBIO ANNOUNCES IND ACTIVE FOR PHASE I/II TRIAL OF RGX-121 TO TREAT MUCOPOLYSACCHARIDOSIS TYPE II.REGENXBIO INC - ‍EXPECT TO COMMENCE TRIAL ENROLLMENT IN FIRST HALF OF 2018 FOR RGX-121​.  Full Article

Regenxbio reports third quarter financial results
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Regenxbio Inc :Regenxbio reports third quarter 2017 financial results and recent operational highlights.Q3 loss per share $0.67.Q3 revenue $1.3 million versus $100,000.Q3 revenue view $1 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.72 -- Thomson Reuters I/B/E/S.Regenxbio Inc - ‍cash, cash equivalents and marketable securities were $191.1 million as of Sept 30, 2017, compared to $159.0 million as of December 31, 2016​.  Full Article